QUOIN PHARMACEUTICALS, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7726 USD | -2.81% |
|
-0.48% | -84.25% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15.19 | 6.884 | 4.842 | 2.848 | - | - |
| Enterprise Value (EV) 1 | 15.19 | 6.884 | 4.842 | 2.848 | 2.848 | 2.848 |
| P/E ratio | -0.34 x | -0.36 x | -0.51 x | -0.33 x | -0.56 x | -5.52 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 0.22 x |
| EV / Revenue | - | - | - | - | - | 0.22 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -32,81,594 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 55.7 | 404 | 987 | 3,686 | - | - |
| Reference price 2 | 273.0 | 17.04 | 4.905 | 0.7726 | 0.7726 | 0.7726 |
| Announcement Date | 14/04/22 | 09/03/23 | 13/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 13.06 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -6.063 | -9.258 | -9.378 | -9.941 | -10.38 | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -21.46 | -9.382 | -8.687 | -10 | -10.38 | -1.828 |
| Net income 1 | -2.095 | -21.46 | -9.447 | -8.687 | -10 | -10.38 | -1.828 |
| Net margin | - | - | - | - | - | - | -14% |
| EPS 2 | -315.0 | -813.0 | -46.80 | -9.640 | -2.310 | -1.370 | -0.1400 |
| Free Cash Flow | - | -4.63 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 16/06/21 | 14/04/22 | 09/03/23 | 13/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.981 | -2.176 | -2.668 | -2.328 | -2.086 | -2.776 | -2.26 | -2.125 | -2.218 | - | -2.515 | -2.557 | -2.601 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.82 | -1.683 | -2.668 | -3.03 | -2.001 | -2.603 | -2.107 | -1.927 | -2.05 | - | -2.515 | -2.557 | -2.601 |
| Net income 1 | -11.82 | -1.683 | -2.668 | -3.095 | -2.001 | -2.603 | -2.107 | -1.927 | -2.05 | - | -2.515 | -2.557 | -2.601 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 634.5 | -30.00 | -38.88 | -11.28 | -4.955 | -4.080 | -2.130 | -1.950 | -2.080 | - | -0.5000 | -0.5000 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 14/04/22 | 23/05/22 | 18/08/22 | 10/11/22 | 09/03/23 | 09/05/23 | 03/08/23 | 09/11/23 | 13/03/24 | 09/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -4.63 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 16/06/21 | 14/04/22 | 09/03/23 | 13/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7726
USD
Average target price
5.8
USD
Spread / Average Target
+650.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -84.25% | 2.85M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- QNRX Stock
- Financials Quoin Pharmaceuticals, Ltd.
